Pharmsynthesis' RAS loss for 3 months of 2026 amounted to ₽36 million, which is two times lower than the ₽74 million loss in the previous year. Revenue decreased by 7.8% to ₽23.6 million, compared to ₽25.6 million a year earlier.

Shareholders of Pharmsintez decided to increase the authorized capital by placing 1.1 billion additional ordinary shares. Securities will be placed by open subscription with payment in cash only. Placement price will be set by the Board of Directors.

Board of Directors of Pharmsintez has called a repeat meeting of shareholders to decide on the placement of 1.1 billion additional ordinary shares of the company. It will be held on February 19th.

Pharmsintez's loss under RAS for 9 months of 2025 amounted to ₽121.2 million, a decrease of 0.5% compared to ₽121.8 million in the previous year. Revenue decreased by 18.3% to ₽101.3 million from ₽124 million a year earlier.